• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dementia and Geriatric Cognitive Disorders Extra >Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer’s Disease Patients from Healthy Subjects
【24h】

Two Blood Monocytic Biomarkers (CCL15 and p21) Combined with the Mini-Mental State Examination Discriminate Alzheimer’s Disease Patients from Healthy Subjects

机译：两种血液单核生物标志物（CCL15和p21）与微弱的精神状态检查相结合，将阿尔茨海默氏病患者与健康受试者区分开

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. In AD, monocytes migrate across the blood-brain barrier and differentiate into microglia, are linked to inflammatory responses and display age-dependent decreases in telomere lengths. Methods: Six monocyte-specific chemokines and the (telomere-associated) tumor suppressor proteins p53 and p21 were determined by multiplex immunoassay in plasma and monocyte extracts of patients with AD or mild cognitive impairment, and levels were compared between patients and controls (without cognitive impairment). Results: CCL15 (macrophage inflammatory protein-1δ), CXCL9 (monokine-induced by interferon-γ) and p21 levels were decreased in monocytes of AD patients compared with controls. Conclusion: The combination of monocytic CCL15 and p21 together with the Mini-Mental State Examination enables to differentiate AD patients from controls with high specificity and sensitivity.
机译：背景：阿尔茨海默氏病（AD）是一种进行性神经退行性疾病。在AD中，单核细胞迁移穿过血脑屏障并分化为小胶质细胞，与炎症反应相关，并显示出端粒长度随年龄而减少。方法：通过多重免疫分析法测定AD或轻度认知障碍患者血浆和单核细胞提取物中的六种单核细胞特异性趋化因子和（端粒相关的）肿瘤抑制蛋白p53和p21，并比较患者和对照组（无认知能力）的水平损害）。结果：与对照组相比，AD患者单核细胞的CCL15（巨噬细胞炎性蛋白-1δ），CXCL9（干扰素-γ诱导的单核细胞因子）和p21水平降低。结论：单核细胞CCL15和p21结合迷你精神状态检查可将AD患者与对照组区别开来，具有高特异性和敏感性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号